Related Experiment Video

Updated: Jun 10, 2026

Isolation, Characterization, and Proteomic Analysis of Plasma-Derived Extracellular Vesicles for Cardiovascular Biomarker Discovery
05:30

Isolation, Characterization, and Proteomic Analysis of Plasma-Derived Extracellular Vesicles for Cardiovascular Biomarker Discovery

Published on: January 31, 2025

Plasma metabolomics reveals biomarkers of the atherosclerosis

Xi Chen1, Lian Liu, Gustavo Palacios

  • 1Institute of Medicinal Plant Development, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing, P. R. China.

Journal of Separation Science
|August 24, 2010
PubMed

Insights

This study identifies altered fatty acid metabolism, particularly palmitate, as a key indicator for diagnosing atherosclerosis. These findings offer potential new biomarkers for early clinical detection of cardiovascular disease.

Area of Science:

  • Biochemistry
  • Cardiovascular Medicine
  • Metabolomics

Background:

  • Atherosclerotic cardiovascular disease is a major cause of death globally.
  • Current clinical diagnosis of atherosclerosis is limited by a lack of reliable metabolite biomarkers.
  • Identifying specific metabolic signatures could improve early detection and management.

Purpose of the Study:

  • To investigate plasma metabolome differences between atherosclerosis patients and healthy individuals.
  • To identify potential metabolite biomarkers for atherosclerosis diagnosis.
  • To confirm the role of specific fatty acids, like palmitate, in atherosclerosis pathogenesis.

Main Methods:

  • Plasma samples were collected from 16 stable atherosclerosis patients and 28 healthy controls.
  • Gas chromatography-mass spectrometry (GC/MS) based metabolomics analysis was performed.
  • Advanced pattern recognition techniques, including PCA, OPLS-DA, and HCA, were employed for data analysis.

Main Results:

  • Significant differences in plasma metabolome were observed between atherosclerotic and non-atherosclerotic subjects.
  • Fatty acid metabolism, including palmitate, stearate, and 1-monolinoleoylglycerol, was notably perturbed in atherosclerosis patients.
  • Palmitate was identified as a significant contributor to atherosclerosis, impacting apoptosis and inflammation pathways.

Conclusions:

  • Atherosclerosis development directly alters fatty acid metabolism.
  • Palmitate is a promising phenotypic biomarker for the clinical diagnosis of atherosclerosis.
  • These findings pave the way for improved diagnostic strategies for cardiovascular disease.

Related Concept Videos

Atherosclerosis I: Introduction01:30

Atherosclerosis I: Introduction

Atherosclerosis is a progressive disorder characterized by the buildup of plaques on the arterial inner wall, causing them to narrow and harden over time. These plaques comprise lipids, calcium, blood components, carbohydrates, and fibrous tissue. The process primarily affects the intima of large and medium-sized arteries, reducing blood flow in any artery.Etiology and risk factorsThe cause of atherosclerosis is multifactorial, involving a complex interplay among endothelial injury, lipid...
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
Atherosclerosis II: Clinical Manifestations and Diagnostic Tests01:27

Atherosclerosis II: Clinical Manifestations and Diagnostic Tests

Atherosclerosis is a progressive disorder that leads to the thickening and narrowing of arterial walls due to plaque buildup. This condition can cause various symptoms depending on the arteries affected:Coronary Artery Disease (CAD): This condition affects the coronary arteries and may lead to chest pain (angina), shortness of breath (dyspnea), heart attacks, and other heart disease symptoms.Cerebrovascular Disease: This affects blood flow to the brain, causing transient ischemic attacks (TIAs)...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Blood Studies for Cardiovascular System I: Cardiac Biomarkers01:20

Blood Studies for Cardiovascular System I: Cardiac Biomarkers

Cardiac biomarkers are enzymes, proteins, and hormones released into the blood when cardiac cells are injured. They are powerful tools for triaging.
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...